Etiology and impact of cytomegalovirus disease on solid organ transplant recipients

American Journal of Health-System Pharmacy

Volumn 63, Issue SUPPL. 5, 2006, Pages

  McDevitt, Lisa M ^a,b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Antivirals; Cytomegalovirus; Immunosuppressive agents; Infections; Transplantaion

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ASPERGILLOSIS; CONFERENCE PAPER; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; EPSTEIN BARR VIRUS; HEART TRANSPLANTATION; HEPATITIS C; HERPES VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REACTIVATION;

EID: 33749163226     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060377     Document Type: Conference Paper

References (52)

1. Straus SE. Introduction to herpesviridae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:1756-81.
2. Sivaraman P, Lye WC. Epstein-Barr virus-associated T-cell lymphoma in solid organ transplant recipients. Biomed Pharmacother. 2001; 55:366-8.
3. Viejo-Borbolla A, Ottinger M, Schulz TF. Human herpesvirus 8: biology and role in the pathogenesis of Kaposi's sarcoma and other AIDS-related malignancies. Curr HIV/AIDS Rep. 2004; 1:5-11.
4. Reschke M. Cytomegalovirus. www. biografix.de (accessed 2006 July 13).
5. Crumpacker CS, Wadhwa S. Cytomegalovirus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:1786-1801.
6. Cytomegalovirus infections. In: Beers MH, Berkow R, eds. The Merck manual of diagnosis and therapy, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:1295-6.
7. Hirsch MS. Cytomegalovirus and human herpesvirus types 6, 7, and 8. In: Kasper DL, Fauci AS, Longo DL et al., eds. Harrison's principles of internal medicine. 16th ed. New York, NY: McGraw-Hill; 2005:1049-53.
8. Froberg MK. Review: CMV escapes! Ann Clin Lab Sci. 2004; 34:123-30.
9. Griffiths PD, Cope AV, Hassan-Walker AF et al. Diagnostic approaches to cytomegalovirus infection in bone marrow and organ transplantation. Transpl Infect Dis. 1999; 1:179-86.
10. Preiksaitis JK, Brennan DC, Fishman J et al. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant. 2005; 5:218-27.
11. Sagedal S, Nordal KP, Hartmann A et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation. 2000; 70:1166-74.
12. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997; 10:86-124.
13. Ho M. Advances in understanding cytomegalovirus infection after transplantation. Transplant Proc. 1994; 26(5 suppl 1):7-11.
14. Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis. 1999; 1:21-8.
15. Lowance D, Neumayer HH, Legendre CM et al. for the International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med. 1999; 340:1462-70.
16. Gane E, Saliba F, Valdecasas GJ et al. for the Oral Gancidovir International Transplantation Study Group. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet. 1997; 350:1729-33.
17. Slifkin M, Tempesti P, Poutsiaka DD et al. for the Boston Center for Liver Transplantation CMVIG Study Group. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis. 2001; 33:E62-8.
18. Falagas ME, Snydman DR, Griffith J et al. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin Infect Dis. 1996; 23:468-74.
19. Munoz-Price LS, Slifkin M, Ruthazer R et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis. 2004; 39:1293-9.
20. Patel R, Portela D, Badley AD et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation. 1996; 62:926-34.
21. Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994; 170:644-52.
22. George MJ, Snydman DR, Werner BG et al. for the Boston Center for Liver Transplantation CMVIG-Study Group. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med. 1997; 103:106-13.
23. Munoz P, Rodriguez C, Bouza E et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant. 2004; 4:636-43.
24. Husni RN, Gordon SM, Longworth DL et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 1998; 26:753-5.
25. Fortun J, Martin-Davila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl. 2002; 8:1065-70.
26. Mendez JC, Dockrell DH, Espy MJ et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis. 2001; 183:179-84.
27. DesJardin JA, Cho E, Supran S et al. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients. Clin Infect Dis. 2001; 33:1358-62.
28. Griffiths PD, Clark DA, Emergy VC. Beta herpesviruses in transplant recipients. J Antimicrob Chemother. 2000; 45(suppl T3):29-34.
29. Kidd IM, Clark DA, Sabin CA et al. Prospective study of human beta herpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation. 2000; 69:2400-4.
30. Hornef MW, Bein G, Fricke L et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation. 1995; 60:474-80.
31. Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis. 1997; 176:1462-7.
32. Razonable RR, Burak KW, van Cruijsen H et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002; 35:974-81.
33. Becker BN, Becker YT, Leverson GE et al. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis. 2002; 39:1088-95.
34. Sagedal S, Nordal KP, Hartmann A et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002; 2:850-6.
35. Toupance O, Bouedjoro-Camus MC, Carquin J et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int. 2000; 13:413-9.
36. Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection-an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation. 1993; 55:851-7.
37. Dickenmann MJ, Cathomas G, Steiger J et al. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation. 2001; 71:764-7.
38. Reischig T, Jindra P, Mares J et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation. 2005; 79:317-24.
39. Giral M, Nguyen JM, Daguin P et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol. 2001; 12:1758-63.
40. Schnitzler MA, Lowell JA, Hmiel SP et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol. 2003; 14:780-5.
41. Humar A, Gillingham KJ, Payne WD et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation. 1999; 68:1879-83.
42. Nett PC, Heisey DM, Fernandez LA et al. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation. 2004; 78:1036-41.
43. Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol. 2003; 23:567-75.
44. Borchers AT, Perez R, Kaysen G et al. Role of cytomegalovirus infection in allograft rejection: a review of possible mechanisms. Transpl Immunol. 1999; 7:75-82.
45. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol. 2000; 20:126-47.
46. Gao LH, Zheng SS. Cytomegalovirus and chronic allograft rejection in liver transplantation. World J Gastroenterol. 2004; 10:1857-61.
47. Scott AI, Sharples LD, Stewart S. Bronchiolitis obliterans syndrome: risk factors and therapeutic strategies. Drugs. 2005; 65:761-71.
48. Opeltz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a Collaborative Transplant Study Report. Am J Transplant. 2004; 4:928-36.
49. Falagas ME, Snydman DR, Griffith J et al. for the Boston Center for Liver Transplantation CMVIG Study Group. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med. 1997; 126:275-9.
50. Ettinger NA, Bailey TC, Trulock EP et al. for the Washington University Lung Transplant Group. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Am Rev Respir Dis. 1993; 147:1017-23.
51. Munoz P, Fogeda M, Bouza E et al. Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis. 2005; 41:1720-5.
52. Alonso O, Loinaz C, Abradelo M et al. Changes in the incidence and severity of recurrent hepatitis C after liver transplantation over 1990-1999. Transplant Proc. 2003; 35:1836-7.